CYTO 2019 Workshop: Assuring Rigor and Reproducibility for use of Mass Cytometry in Clinical Research
The addition of mass cytometry to the pool of technologies in clinical studies requires more standardization and quality control. Discussion on the use of CyTOF assays for clinical research including panel design and validation, reagents and protocols for sample processing, instrument operation, quality control, regulatory oversight and data analysis is needed. We hope to bring together experts in the field at CYTO 2019 to learn from their experiences and discuss how best to overcome these challenges.
1. Are you currently using Mass Cytometry? More than one response can be selected.
2. If you are currently NOT using Mass Cytometry, what is preventing you from using this technology? More than one response can be selected.
3. What type of clinical studies/research do you use Mass Cytometry for? More than one response can be selected.
4. Which area(s) in the CyTOF workflow do you struggle with? More than one response can be selected.
5a. Regarding experimental design, what are the main challenges you have encountered? More than one response can be selected.
5b. How have you attempted to solve these main challenges?
6a. Regarding reagent availability, what are the main challenges you have encountered? More than one response can be selected
6b. How have you attempted to solve these main challenges?
7a. Regarding protocol optimization, what are the main challenges you have encountered? More than one response can be selected.
7b. How have you attempted to solve these main challenges?
8a. Regarding panel design and validation, what are the main challenges you have encountered? More than one response can be selected.
8b. How have you attempted to solve these main challenges?
9a. Regarding sample processing, what are the main challenges you have encountered? More than one response can be selected.
9b How have you attempted to solve these main issues?
10a. Regarding instrumentation, what are the main challenges you have encountered? More than one response can be selected.
10b. How have you attempted to solve these main challenges?
11a. Regarding quality control, what are the main challenges you have encountered? More than one response can be selected.
11b. How have you attempted to solve these main challenges?
12. Regarding software/data analysis and statistical evaluation, what are the main challenges you have encountered? More than one response can be selected.
12b. How have you attempted to solve these main challenges?
13. Regarding industry regulation, what are the main challenges you have encountered? More than one response can be selected.
14. How do you typically account for batch effects with CyTOF data?
Clear selection
15. What platform do you use for CyTOF data analysis?
Clear selection
16. Do you think CyTOF is mature enough to be used in clinical trials?
Clear selection
Submit
Never submit passwords through Google Forms.
This content is neither created nor endorsed by Google. Report Abuse - Terms of Service - Privacy Policy